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Background. 18F-Fluoride uptake denotes calcification activity in aortic stenosis and
atherosclerosis. While PET/MR has several advantages over PET/CT, attenuation correction of
PET/MR data is challenging, limiting cardiovascular application. We compared PET/MR and
PET/CT assessments of 18F-fluoride uptake in the aortic valve and coronary arteries.
Methods and results. 18 patients with aortic stenosis or recent myocardial infarction
underwent 18F-fluoride PET/CT followed immediately by PET/MR. Valve and coronary 18F-
fluoride uptake were evaluated independently. Both standard (Dixon) and novel radial GRE)
MR attenuation correction (AC) maps were validated against PET/CT with results expressed as
tissue-to-background ratios (TBRs). Visually, aortic valve 18F-fluoride uptake was similar on
PET/CT and PET/MR. TBRMAX values were comparable with radial GRE AC (PET/CT
1.55±0.33 vs. PET/MR 1.58 ± 0.34, P 5 0.66; 95% limits of agreement 2 27% to 1 25%) but
performed less well with Dixon AC (1.38 ± 0.44, P 5 0.06; bias (2)14%; 95% limits of
agreement 2 25% to 1 53%). In native coronaries, 18F-fluoride uptake was similar on PET/
MR to PET/CT regardless of AC approach. PET/MR identified 28/29 plaques identified on
PET/CT; however, stents caused artifact on PET/MR making assessment of 18F-fluoride uptake
challenging.
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Conclusion. Cardiovascular PET/MR demonstrates good visual and quantitative agree-
ment with PET/CT. However, PET/MR is hampered by stent-related artifacts currently
limiting clinical application. (J Nucl Cardiol 2019)
Key Words: PET Æ PET/MR Æ PET/CT Æ atherothrombosis Æ aortic stenosis Æ myocardial
infarction Æ CMR
Abbreviations
PET/CT Positron Emission Tomography/Com-
puterized Tomography
PET/MR Positron Emission Tomography/Mag-
netic Resonance
MRAC Magnetic Resonance Attenuation
Correction
GRE Gradient Recalled Echo
LGE Late Gadolinium Enhancement
SUVMEAN Standardized Uptake Value mean
SUVMAX Standardized Uptake value max
TBRMEAN Target-to-Background Ratio mean
TBRMAX Target-to-Background Ratio max
OSEM Ordered Subsets Expectation
Maximization
INTRODUCTION
Calcification is a key pathological process in both
aortic stenosis and coronary atherosclerosis. The devel-
opment of 18F-fluoride imaging now allows calcification
activity to be imaged directly, providing a marker of
disease activity in aortic stenosis and coronary
atherosclerosis with potential to improve patient risk
stratification.
To date, cardiac studies investigating the uptake of
18F-fluoride have predominantly employed hybrid PET/
CT, but interest has recently developed in Positron
Emission Tomography/Magnetic Resonance (PET/MR)
platforms. PET/MR provides several potential advan-
tages compared to PET/CT including reduced radiation
exposure, integrated functional assessment, improved
soft tissue characterisation and motion correction.1
While PET/MR has already shown promise in the
assessment of aortic stenosis,2 coronary atherosclerosis,3
cardiac amyloidosis and sarcoidosis,4,5 it remains
unclear how the pattern and intensity of tracer uptake
compares with the current gold-standard of PET/CT.
This is of particular importance given concerns regard-
ing the optimal method for attenuation correction on
PET/MR.
MR-based attenuation correction maps are based on
proton density,6 with two current approaches. The Dixon
MR AC map is the standard approach but is hampered in
cardiac studies due to both motion artifact (along the
heart–lung and liver–lung interfaces) and mis-segmen-
tation of the bronchi as soft tissue. A novel free-
breathing radial GRE (Gradient Recalled Echo)
approach was developed to try to overcome these
issues.3 Concerns remain for both techniques about the
impact of intra-coronary stents on attenuation
correction.
We aimed to validate PET/MR (using both the
Dixon and radial GRE attenuation correction approa-
ches) against PET/CT in patients undergoing the two
paired scans. In particular, we sought to compare the
pattern of aortic valve and coronary 18F-fluoride uptake
on PET/MR and PET/CT and to investigate whether
quantification of tracer uptake in these regions differs
between the two imaging approaches.
METHODS
Study subjects from two ongoing 18F-fluoride PET/CT
trials were approached regarding participation in the current
study and having a PET/MR scan immediately following their
PET/CT. The SALTIRE 2 trial (Bisphosphonates and RANKL
Inhibition in Aortic Stenosis, NCT02132026) recruited patients
aged over 50 years with a peak aortic jet velocity of[2.5 m/s
and grade 2-4 calcification of the aortic valve on echocardio-
graphy. The PRE18FFIR trial (Prediction of recurrent events
with 18F-fluoride to identify ruptured and high-risk coronary
artery plaques in patients with myocardial infarction,
NCT02278211) recruited patients with recent myocardial
infarction and multi-vessel coronary artery disease on invasive
angiography. Exclusion criteria for both trials include inability
to receive iodinated contrast, renal impairment (estimated
glomerular filtration rate B30 mL/min/1.73 m2) or women of
child-bearing potential. This PET/CT and PET/MR compar-
ison study was approved by the Scottish Research Ethics
Committee and the United Kingdom (UK) Administration of
Radiation Substances Advisory Committee. It was performed
in accordance with the Declaration of Helsinki. All patients
provided written informed consent prior to any study
procedures.
18F-Fluoride Positron Emission Tomography
and Coronary Computed Tomography
Angiography
All patients underwent a single 18F-fluoride PET/CT scan.
Patients were administered 50-100 mg oral metoprolol if their
resting heart rate was[65 beats/min prior to the intravenous
administration of 125 MBq 18F-fluoride (aortic stenosis cohort)
or 250 MBq 18F-fluoride (myocardial infarction cohort). After
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60 minutes, patients were imaged with a hybrid PET/CT
scanner (64-multidetector Biograph mCT, Siemens Healthcare
GmbH, Erlangen, Germany). CT attenuation correction scans
were performed as follows; Helical and on inspiration at 120
kV with mA adjusted to body habitus. The pitch was 0.8, slice
thickness 5 mm rotation time 500 ms. PET-emission scans
were then acquired in list-mode format (30 minutes).
All patients in the PRE18FFIR myocardial infarction
cohort received sublingual glyceryl trinitrate prior to CCTA.
CT effective dose was calculated by multiplying the dose
length product (mGy  cm) by a conversion factor (0.014 mSv/
mGy  cm).
18F-Fluoride Positron Emission Tomography
and Coronary Magnetic Resonance
Angiography
Immediately after the PET/CT scan all participants were
transferred onto the hybrid PET/MR system (Biograph mMR,
Siemens Healthcare GmbH, Erlangen, Germany) for simulta-
neous 18F-fluoride PET/MR imaging. PET data were acquired
for 50 minutes in list-mode, starting approximately 120
minutes after intravenous injection of 18F-fluoride. Both
standard breath-held 3D Dixon-VIBE7 (Dixon) and free-
breathing radial gradient echo (GRE, Siemens work-in-pro-
gress #793F) sequences were acquired for MR attenuation
correction with the subjects arms down (HUGE sequence not
employed). The free-breathing radial GRE attenuation correc-
tion map was generated during PET acquisition (for 4 minutes
52 seconds) using the method described by Robson et al6 The
MR protocol also included coronary magnetic resonance
angiography (CMRA) performed with 0.2 mmol/kg of intra-
venous gadobutrol contrast (Gadovist, Bayer Pharma AG,
Germany) and late gadolinium enhancement imaging 10-15
minutes post contrast administration. The total MRI scan
duration was approximately 60 minutes.
Image Reconstruction
Both PET/CT and PET/MR off-line PET reconstructions
were carried out using e7tools (Siemens Healthcare). The full
list-mode acquisitions were reconstructed without time-of-
flight correction or resolution modeling. Ordered Subsets
Expectation Maximization (OSEM) algorithm with the fol-
lowing parameters were employed: 256 9 256 field of view, 4
iterations, 21 subsets, 5 mm Gaussian filter. The CT was used
for attenuation correction of the PET/CT data. PET data
acquired on PET/MR were first reconstructed applying the
standard Dixon attenuation correction method (4 tissue class
segmentation; air, lung, soft tissue and fat). PET data were then
also reconstructed applying a custom MR attenuation correc-
tion map derived from the free-breathing radial GRE sequence
[2 tissue classes: background (air and lung) and soft tissue (soft
tissue and fat)].3,8 ECG gating was not applied for either
modality.
PET/CT and PET/MR Image Analysis
Accurate co-registration was achieved by aligning 18F-
fluoride activity in the blood pool and ascending aorta with the
corresponding anatomical structures on the CCTA.9 Qualita-
tive and semi-quantitative analysis of the PET images from all
18 scans was performed independently by a trained observer
(J.P.M.A.) using FusionQuant software (Version 1, Cedars-
Sinai Medical Center, Los Angeles, USA). Radiotracer uptake
was analyzed using a standardized protocol (Supplemental
data). For aortic valve analysis, polygons of 6-mm depth were
drawn around the perimeter of the valve on the co-registered
co-axial image to generate a region of interest (ROI)
(Figure 1C, H?M yellow dotted line).10 Coronary arteries
with a diameter C 2 mm were assessed according to the 18-
segment Society of Cardiac Computed Tomography model.11
Coronary uptake was considered positive if an area of
increased activity originated in a diseased coronary artery
and followed its course for[ 5 mm in 3 dimensions across
orthogonal views.12 Standardized uptake values (SUVMAX)
were calculated for all ROIs and corrected for blood pool
activity (measured in the right atrium13) to generate tissue-to-
background ratios (TBRMAX).
A previous study evaluating the diagnostic effect of a
prolonged circulation time on coronary uptake, established that
imaging at later time points following tracer injections did not
affect SUV values but increased TBR values predominantly as
a result of increased tracer clearance from the blood pool.12
We therefore applied a previously validated correction factor
that compensates for this effect and the fact that patients were
imaged at a later time point with PET/MR than PET/CT.14
This approach individually corrects all SUV measurements of
blood pool activity (accounting for transfer time between
scanners) to a standard 60-min time point post-injection,
thereby correcting our calculated PET/CT and PET/MR TBR
values for differences in injection-to-scan time (Suppl.
Figure 1).
Statistical Analysis
Statistical analyses were performed using GraphPad
Prism Version 7.0 and SPSS Version 23. A two-sided
P\ 0.05 was considered statistically significant. The distri-
bution of all continuous variables was assessed using the
D’Agostino and Pearson test, which were presented using
mean ± standard deviation of the mean or median [interquar-
tile range]. Comparisons between groups were performed
using the two-sample t test, one-way ANOVA (paired where
appropriate), Bland–Altman method of comparison, intra-class
correlation coefficient (with 95% confidence intervals for
Figure 1. Correction factor formula to compensate for vari-
ations in injection-to-scan interval. ‘t’ represents tracer
circulating time prior to PET imaging.
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continuous measurements) and Kappa statistic where appro-
priate. All categorical variables are presented as percentages.
RESULTS
Patients
A total of 18 patients (mean age 67 ± 7 years, 16
male; Table 1) were recruited and completed both PET/
CT and PET/MR scans of the aortic valve and coronary
arteries: 7 with aortic stenosis and 11 with recent
myocardial infarction. There was no difference in net
PET counts on the 30 minutes PET/CT compared to the
50 minutes PET/MR (P = 0.66). CT exposure added
4.3 ± 1.2 mSv (49%) to the overall total effective
radiation dose (8.8 mSv).
Qualitative Image Quality
When the standard Dixon AC technique was used,
substantial extra-cardiac artifact affected PET/MR
image interpretation in all 18 study participants. These
consisted of increased tracer activity in the bronchial
tree and at the heart-lung and liver interfaces as
previously described.3 The free-breathing radial GRE
attenuation correction map eliminated these artifacts on
all the PET/MR scans (Suppl. Figure 2). None of these
extra-cardiac artifacts were present on the PET/CT
scans.
Aortic Stenosis
Intense aortic valve 18F-fluoride uptake was
observed in all seven patients with aortic stenosis on
both PET/CT and PET/MR (Figure 2). Moreover, the
pattern of tracer uptake with the valve was similar across
the two modalities, localizing predominantly to the tips
of the valve leaflets and the commissures (Figure 2).
Aortic valve TBRMAX values were higher in
patients with aortic stenosis than those without: 44%
higher using PET/CT, 30% using radial GRE PET/MR
and 37% using Dixon PET/MR (Suppl. Figure 3).
Across the cohort as a whole, aortic valve SUVMAX
values were higher on PET/CT than PET/MR irrespec-
tive of the attenuation correction approach (Table 2).
Similarly, right atrial blood pool SUV values were
higher on PET/CT than both PET/MR attenuation
correction techniques even after correcting for differ-
ences in injection-to-scan time (Table 2). These two
effects canceled each other out so TBR values were
similar on PET/MR compared to PET/CT (Figure 3A, B
and Table 2).
On Bland–Altman analysis, there were no fixed or
proportional biases in TBRMAX values between radial
GRE PET/MR and PET/CT (bias - 1% limits of
agreement - 27% to ? 25%) (Figure 3B; Table 3).
Intra-class correlation coefficient (ICC) was good to
excellent at 0.878. Agreement between Dixon PET/MR
and PET/CT TBRMAX values remained good but was
less strong (14% bias, limits of agreement - 25% to
Table 1. Participant demographics
Whole
cohort
(n 5 18)
Aortic
Stenosis
(n 5 7)
Myocardial
Infarction
(n 5 11)
Age 67 (56–78) 69 (57–78) 67 (59–76)
Male 16/18 (89%) 6/7 (86%) 10/11 (91%)
Smoking (ex or current) 5/18 (28%) 1/7 (14%) 4/11 (36%)
Hypertension 7/18 (39%) 3/7 (43%) 4/11 (36%)
Hyperlipidaemia 10/18 (56%) 4/7 (57%) 6/11 (55%)
Diabetes 1/18 (6%) 1/7 (14%) 0/11 (0%)
Previous myocardial Infarction 12/18 (67%) 1/7 (14%) 11/11 (100%)
Previous PCI 13/18 (72%) 2/7 (29%) 11/11 (100%)
Administered dose 18F-Fluoride (MBq) 193.7 ± 61.5 119.4 ± 6.2 241.6 ± 8.0
PET effective radiation dose (mSv) 4.5 3 6
CT Dose Length Product (mGy/cm) 310.1 ± 89.3 336.1 ± 32.9 293.5 ± 110.1
CT effective radiation dose (mSv) 4.3 ± 1.2 4.7 ± 0.5 4.1 ± 1.5
PET/CT injection-to-scan interval (mins) 62 ± 5 61 ± 2 63 ± 5
PET/MR injection-to-scan interval (mins) 136 ± 16 123 ± 5 143 ± 18
CT, Computerized Tomography; MBq, megabecquerels; mGy/cm, milligrays/centimeter, mins, minutes; mSv, millisievert; PCI,
Percutaneous Coronary Intervention; PET/MR, Positron Emission Tomography/Magnetic Resonance
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? 53%; ICC = 0.794, Figure 3E; Table 2). Generally,
agreement between TBRMEAN values on PET/CT and
PET/MR was less good than for TBRMAX (Table 2).
Coronary 18F-Fluoride Uptake
Visual agreement in determining coronary 18F-
fluoride uptake on PET/CT and PET/MR was generally
good in non-stented regions. Across the total population,
a total of 28 (1.56 plaques/patient) non-stented coronary
plaques demonstrated increased 18F-fluoride uptake on
PET/CT. PET/MR identified excellent agreement with
increased uptake in 28 (97%) of these lesions irrespec-
tive of the method of attenuation correction (j 0.93, CI
0.837 to 1.000). Four plaques demonstrated increased
18F-fluoride uptake on the PET/MR scans but not on
PET/CT.
In the native coronary arteries, SUVMAX values
were lower on PET/MR (using both attenuation correc-
tion techniques) than on PET/CT consistent with
findings in the valve. TBRMAX values were comparable,
although slightly higher using GRE PET/MR than PET/
CT (bias - 11%, limits of agreement - 54% to 32%;
Table 3; Figure 4B, 5).
Coronary stents caused severe artifact on both the
radial GRE and Dixon MR attenuation correction maps,
resulting in marked dropout of the PET signal and
precluding accurate analysis. Agreement between PET/
CT and PET/MR in determining 18F-fluoride uptake
within coronary stents was therefore poor (Table 3).
Increased 18F-fluoride uptake was observed on PET/CT
in 18 coronary stent segments. On radial GRE PET/MR,
18F-fluoride uptake in the body of the stent was obscured
by artifact in all 18 stents, although increased uptake
Figure 2. 18F-Fluoride uptake in a patient with moderate aortic stenosis. The columns represent the
imaging modality and rows the corresponding view. (A, F, G) Calcification of the aortic valve
(non-coronary cusp predominantly, yellow arrows). (B, G, L) The coronary magnetic resonance
angiogram in the same views. Calcification cannot be appreciated on MR but the raphe between the
non-coronary cusp and left coronary cusp appears thickened (B). PET/CT shows uptake overlaying
these areas of calcification (C, H,M). Note the uptake also over the calcified mitral annulus (M, red
arrow) and arterial wall of the descending aorta (M, red arrow). Radial GRE-fused PET/MR shows
18F-fluoride uptake in the same areas as the PET/CT (D, I, N). (E, J, O) The corresponding views in
the Dixon PET/MR attenuation correction map. Again 18F-Fluoride follows a similar pattern to
PET/CT but note the image artifact in (O) (white arrow).
Journal of Nuclear Cardiology Andrews et al
Cardiovascular 18F-fluoride positron emission tomography-magnetic resonance imaging
could be appreciated either at the proximal or distal end
of the stent in 6 cases. Artifact was also observed with
Dixon PET/MR, although it was less pronounced than
the radial GRE PET/MR (Figure 4O), with increased
18F-fluoride activity observed at the margins of the stent
in 7 cases (Suppl. Figure 3). Interestingly this artifact
was not present in heavily calcified arteries or valves on
either PET/MR AC map. The differences in tissue
classification between both PET/MR attenuation maps
can be further appreciated in Supplementary Figure 1.
DISCUSSION
We have compared 18F-fluoride PET/MR with PET/
CT imaging of the aortic valve and coronary arteries in
cohorts of patients with aortic stenosis or coronary heart
disease. We have shown that the pattern of 18F-fluoride
uptake within the aortic valve and in non-stented
coronaries is similar on both scans, although coronary
PET/MR is limited by artifact at the site of intra-
coronary stent implantation. Quantitatively, across both
valve and non-stented coronary arteries SUVMAX uptake
values are greater on PET/CT than PET/MR. This
difference is however corrected for in the calculation of
TBRMAX values thereby supporting the future use of
18F-fluoride PET/MR in the investigation of aortic
stenosis and coronary atherosclerosis.
In this study, we have explored two different MR
methods of attenuation correction and made comparison
with PET/CT as the reference standard arbitrator. As
previously reported, we have demonstrated that Dixon is
consistently affected by extra-cardiac artifacts in the
bronchus and heart–lung and lung–diaphragm interfaces.
This problem is resolved with the use of a free-breathing
radial GRE attenuation correction sequence which also
consistently provided improved agreement with PET/
CT-derived TBR and SUV values. We would therefore
recommend use of the radial GRE attenuation correction
method in cardiovascular PET/MR studies.
Table 2. Comparison of aortic valve standardized uptake values and tissue-to-background values
between PET/CT and both PET/MR attenuation correction maps in all patients
PET/CT
PET/MR
(radial
GRE)
Agreement PET/CT vs
PET/MR (radial GRE)
PET/MR
(Dixon)
Agreement PET/
CT vs PET/MR
(Dixon)
Aortic valve
SUVMAX
(n = 18)
1.76 ± 0.56 1.23 ± 0.38 P =\0.01 1.22 ± 0.43 P =\0.01
95% LoA = - 14% to 84% 95% LoA = - 3% to
77%
Bias = 35% Bias = 37%
Aortic valve
SUVMEAN
1.35 ± 0.34 0.89 ± 0.26 P =\0.01 0.85 ± 0.26 P =\0.01
95% LoA = - 15% to 97% 95% LoA = 10% to
82%
Bias = 42% Bias = 47%
TC Aortic valve
TBRMAX
1.55 ± 0.33 1.58 ± 0.34 P =[0.99 1.38 ± 0.44 P = 0.06
95% LoA = - 28% to 25% 95% LoA = - 25% to
53%
Bias = - 1% Bias = 13%
TC Aortic valve
TBRMEAN
1.21 ± 0.18 1.12 ± 0.15 P = 0.08 0.90 ± 0.24 P =\0.01
95% LoA = - 19% to 34% 95% LoA = - 9% to
59%
Bias = 8% Bias = 25%
TC Right atrium
SUVMEAN
1.14 ± 0.24 0.80 ± 0.23 P =\0.01 0.90 ± 0.25 P =\0.01
95% LoA = - 24% to 98% 95% LoA = - 31% to
79%
Bias = 36% Bias = 24%
PET/CT, Positron Emission Tomography/Computerized Tomography; PET/MR, Positron Emission Tomography/Magnetic
Resonance; SUV, standardized uptake value; TBR, tissue-to-background ratio; TC, time-corrected
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18F-fluoride PET/CT quantifies calcification activity
and predicts disease progression in aortic stenosis and
other valve conditions.13,15–17 It is currently being
explored as an efficacy endpoint in studies of novel
therapies for aortic stenosis including the SALTIRE 2
(NCT02132026) randomized controlled trial. If tracer
uptake could also be quantified with PET/MR then this
modality would hold many advantages, not least the
greatly reduced radiation exposure: a particularly impor-
tant consideration given the need in such trials for serial
scans. 18F-Fluoride PET/MR is being explored as an
efficacy endpoint for these exact reasons in the BASIK 2
trial (Bicuspid Aortic Valve Stenosis and the Effect of
Vitamin K2 on Calcification Using 18F -Sodium Fluo-
ride Positron Emission Tomography/Magnetic
Resonance, NCT02917525).18 Establishing whether
PET/MR provides similar results to PET/CT is therefore
important.
In this study, we have demonstrated that the pattern
of valvular 18F-fluoride uptake on PET/MR was reas-
suringly similar to that observed on PET/CT, with high
intensity uptake localizing to the valve in all 7 patients
with aortic stenosis (Figure 1 and Suppl. Fig-
ure 3).10,13,14 Interestingly, this uptake appeared to
localize to the leaflet edges and the commissures: the
sites of maximal mechanical stress within the valve.
Imaging of the coronary arteries with PET/MR does
present additional challenges driven by the small size
and complex motion of the coronary arteries. We have
demonstrated successful use of Gadobutrol contrast for
CMRA (when administered as a slow infusion). This
CMRA technique allowed clear appreciation of the
proximal two-thirds of each epicardial artery (Fig-
ure 3B) facilitating localisation of 18F-uptake to the
coronary arteries.
As with previous studies,15,16 uptake of 18F-fluoride
in culprit coronary plaques post myocardial infarction
was common. Moreover, the pattern of 18F-fluoride
uptake in native coronary arteries on PET/CT and PET/
MR was very similar, with 28 of the 29 plaques with
increased tracer activity on PET/CT also identified on
PET/MR. Radial GRE PET/MR TBRMAX values in
these areas were again comparable to PET/CT although
limits of agreement were slightly wider than for the
valve. This may reflect partial volume effects or subtle
differences in PET/MR tissue classification at the
cardiac-lung boundary of the AC maps. Our data are
also consistent with the original findings by Robson
Figure 3. Comparison of PET/CT vs both PET/MR attenuation correction techniques when
sampling the aortic valve. (A) A direct comparison of mean TBRMAX of
18F-fluoride uptake on the
aortic valve on PET/CT and radial GRE PET/MR (mean with standard deviation). (B) The Bland–
Altman comparison of 18F-fluoride uptake in the aortic valve between PET/CT and radial GRE
PET/MR. (C) The correlation and R2 value between PET/CT and radial GRE PET/MR. (D-F) The
respective comparison between PET/CT and Dixon PET/MR. Note the significant difference in
mean TBRMAX (D), wider limits of agreement on the Bland–Altman plot (E), and lower R
2 value
on the correlation plot (F).
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et al3 as we observed higher coronary TBRMAX values
on radial GRE PET/MR compared to Dixon although
quantitative agreement with PET/CT was less good
(Figure 5B).
Unfortunately, coronary PET/MR is greatly ham-
pered by artifact at the site of intra-coronary stent
implantation. This is due to magnetic field inhomo-
geneities and subsequent MR signal loss affecting
attenuation correction of the PET data (Suppl. Figure 1).
It was particularly prevalent with radial GRE PET/MR,
where substantial ‘halo’ like PET dropout occurred at
the site of all stents imaged (Figure 4I?N and Suppl.
Figure 3B). Although less dramatic with the Dixon PET/
MR scans, the degree of artifact was such that reliable
interpretation of PET signal remained impossible
(Suppl. Figure 3C). Attempts to overcome this limita-
tion using novel MR gap-filling algorithms have shown
early promise.19 Interestingly, areas of dense coronary
and valvular calcification were not affected by PET
dropout.
Discrepancies were observed when comparing SUV
values in the valve and coronary arteries measured by
PET/CT and PET/MR approaches (Tables 2, 3). SUV
values were consistently higher on PET/CT than PET/
MR. This may be explained by basic differences in the
cardiac PET/CT and PET/MR imaging protocols. First,
approaches to attenuation correction are fundamentally
different between PET/CT and PET/MR. Second PET/
CT requires the patients’ arms to be held above their
head. This is designed to not only reduce radiation dose
but also to minimize photon attenuation under the
shoulders and reduce beam hardening artifacts.20 The
bore of the PET/MR scanner is much smaller, and the
arms are therefore held by the patients’ side. This
undoubtedly causes minor shifts in cardiac position
affecting PET photon lines of response, attenuation and
subsequent SUV values.21,22 A paired 18F-fluoride
carotid artery study would help quantify the true
difference (free from photon attenuation by the arms)
between PET/CT and PET/MR. Thirdly, the injection-
to-scan interval was longer for PET/MR than PET/CT.
Given 18F-fluoride SUV values have been shown to
remain unaltered between 1 and 3 hours of PET/CT
imaging,14 inter-modality SUV disparity is therefore
most likely attributable to the above technical differ-
ences (e.g., MR coils23) between PET/CT and PET/MR
scanners.
In contrast TBR values were similar on PET/CT and
PET/MR. Adjustment for blood pool activity effectively
corrected TBR values for the between-scanner differ-
ences in PET SUV quantification outlined above.
Moreover, we adjusted TBR values for differences in
Table 3. Comparison of time-corrected coronary standardized uptake values and tissue-to-
background values between PET/CT and both PET/MR maps in all patients
PET/CT
(60
minutes)
PET/MR
(radial
GRE)
Agreement PET/CT
vs PET/MR (radial
GRE)
PET/MR
(Dixon)
Agreement PET/
CT vs PET/MR
(Dixon)
Non-stented coronary
plaque SUVMAX
(n = 28)
1.08 ± 0.29 0.85 ± 0.28 P =\0.01 0.86 ± 0.24 P =\0.01
95% LoA = - 48% to
97%
95% LoA = - 32% to
77%
Bias = 25% Bias = 32%
Stented coronary
SUVMAX (n = 18)
1.34 ± 0.33 0.47 ± 0.25 P =\0.01 0.77 ± 0.18 P =\0.01
95% LoA = 3% to 191% 95% LoA = - 9% to
114%
Bias = % Bias = 52%
TC non-stented
coronary plaque
TBRMAX (n = 28)
1.09 ± 0.19 1.24 ± 0.27 P = 0.03 1.09 ± 0.26 P =[0.99
95% LoA = - 54% to
31%
95% LoA = - 41% to
42%
Bias = - 11% Bias = 1%
TC stented coronary
TBRMAX (n = 18)
1.28 ± 0.34 0.58 ± 0.31 P =\0.01 0.89 ± 0.24 P =\0.01
95% LoA = - 14% to
172%
95% LoA = - 5% to
75%
Bias = 79% Bias = 359%
PET/CT, Positron Emission Tomography/Computerized Tomography; PET/MR, Positron Emission Tomography/Magnetic
Resonance; SUV, standardized uptake value; TBR, tissue-to-background ratio; TC, time-corrected
Andrews et al Journal of Nuclear Cardiology
Cardiovascular 18F-fluoride positron emission tomography-magnetic resonance imaging
Figure 4. Influence of stents on coronary artery 18F-fluoride uptake. Each row represents a patient
and the columns the imaging modality. Patient 1: Axial view of complex calcified plaque in the
proximal left anterior descending artery (pLAD) (yellow arrow, A) on CCTA. The corresponding
CMRA can be appreciated in (B). PET/CT (C) shows focal uptake overlying the complex plaque in
the pLAD (yellow arrow) and uptake in the medial wall of the aorta. Both the radial GRE (D) and
Dixon PET/MR (E) demonstrate focal uptake within the LAD plaque (yellow arrows) as the PET/
CT. However, note the absence of uptake within the aorta demonstrating the utility of later imaging
in improving signal-to-noise ratios. Also note airway artifact behind the behind the left atrium and
superior vena cava (red arrows) with the Dixon PET/MR (E). Patient 2: Anterior myocardial
infarction with primary PCI to the LAD. (F) The 2-chamber view of the metallic stent on the CCTA
(yellow arrow). (G) The corresponding CMRA. Focal 18F-fluoride uptake can be appreciated on the
PET/CT within the body of the stent (H, yellow arrow). (I) The radial GRE PET/MR affected by
severe PET dropout over the whole stent despite marked amplification of the blood pool.
Employing the Dixon AC map sees the culprit artery signal within the LAD stent return (J, yellow
arrow). Patient 3: Modified short-axis CCTA with stent in the proximal RCA (yellow arrow). (L)
The corresponding CMRA image of the stent (yellow arrow). (M) Focal 18F-fluoride uptake over
the body of the stent (yellow arrow) on PET/CT. Radial GRE PET/MR shows PET dropout over the
body of the stent (N, yellow arrow). Similarly, Dixon PET/MR is affected by the same artifact
precluding assessment of PET activity within the stent (O, yellow arrow). Patient 4: Short-axis
CCTA (P) shows a diseased right coronary artery (RCA) and a stent placed in the pLAD (yellow
arrow) after primary PCI. Corresponding CMRA can be appreciated in (Q). Uptake within the
proximal to mid RCA (red arrow) and culprit LAD (yellow arrow) can be appreciated on the PET/
CT (R). PET/MR also shows focal 18F-fluoride uptake in the mid RCA with radial GRE PET/MR
(S, red arrow) but note the absence of LAD uptake in the region of the stent (yellow arrow). On
Dixon PET/MR (T), the LAD uptake is visible (yellow arrow) alongside focal RCA uptake (red
arrow).
Journal of Nuclear Cardiology Andrews et al
Cardiovascular 18F-fluoride positron emission tomography-magnetic resonance imaging
injection-to-scan time. After these corrections, we found
no differences in uptake values between PET/CT and
radial GRE PET/MR (Figure 3; Table 2) over the aortic
valve. In non-stented coronary arteries, TBR values
tended to be higher on PET/MR than PET/CT allowing
easier scan interpretation and highlighting the advan-
tages of later time point imaging (Table 3; Figure 4).14
This study is unique in performing cardiac PET/MR
immediately after PET/CT, allowing the fairest com-
parison between the modalities. Nevertheless, there are a
number of limitations. Firstly, there are the unavoidable
differences in injection-to-scan time for the PET/CT and
PET/MR scans. Whilst we have employed measures to
correct for this impact an alternative approach would
have been to scan subjects with PET/CT and PET/MR
on two separate occasions. However, this approach
would cause other problems that are not as easily fixed
as differences in injection-to-scan time. In particular it
would involve differences in the injected dose of tracer,
small differences in scan to injection time, differences
related to variation in the biodistribution of tracer on
different days and most importantly increased exposure
of patients to ionizing radiation. Second, this was a
small pilot investigational study and we would welcome
confirmation of our findings in a larger study, with
further investigation of quantitative agreement between
PET/CT and PET/MR in particular. Third, whilst the
observed agreements between PET/CT and PET/MR are
Figure 5. Comparison of PET/CT vs both PET/MR attenuation correction techniques when
sampling non-stented coronary uptake. (A) A direct comparison of mean TBRMAX of
18F-fluoride
uptake in non-stented coronaries on PET/CT and radial GRE PET/MR (mean with standard
deviation). Note how uptake is significantly higher with radial GRE PET/MR when compared to
PET/CT. (B) The Bland–Altman comparison (with 95% limits of agreement) of coronary 18F-
fluoride uptake between PET/CT and radial GRE PET/MR. (C) The correlation and R2 value
between PET/CT and radial GRE PET/MR in non-stented coronaries. (D-F) The respective
comparison between PET/CT and Dixon PET/MR. Note the lower mean TBRMAX for Dixon PET/
MR when compared to radial GRE (D). Dixon PET/MR had less bias on the Bland–Altman plot (B)
and a higher R2 value on the correlation plot (F).
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encouraging, there are several technical strategies not
employed here that could be used to enhance this
agreement further. In order to make a fair comparison
between modalities, PET data for both PET/CT and
PET/MR were not ECG gated nor was time of flight
employed. This rendered PET uptake susceptible to
motion artifact. Correcting for motion has consistently
been shown to improve coronary discrimination and
TBR values.24–27 Fourth, whilst the radial GRE atten-
uation correction technique reduced PET artifact and
generally improved TBR values, it only includes two
tissue classes (background air and soft tissue). Increas-
ing the amount of tissue classes is likely to improve
uptake discrimination and tracer quantification. Apply-
ing the CT attenuation correction map to the PET/MR
data is one potential method to assess the precision of
both PET/MR attenuation correction maps with the
ground truth but arm position remains a limiting factor.
Finally, in the era of machine learning, it may be
possible to create a pseudoCT attenuation correction
map from the MR data and if accurate, would advance
the use of the PET/MR as a valid alternative to PET/
CT.28
In conclusion, valvular and coronary 18F-fluoride
activity on PET/MR closely matched that observed on
PET/CT. Although SUV values differ between PET/CT
and PET/MR, the use of TBR values effectively corrects
for inter-scanner differences. These data help validate
cardiovascular PET/MR imaging, and supports its future
investigation of cardiovascular disease, in particular
given its advantages in enhanced soft tissue character-
isation and reduced radiation exposure.
NEW KNOWLEDGE GAINED
• The pattern of 18F-fluoride uptake within the aortic
valve and in non-stented coronaries is similar on PET/
CT and PET/MR; however, coronary PET/MR is
limited by magnetic inhomogeneities at the site of
stent implantation.
• Across both valve and non-stented coronary arteries
SUVMAX uptake values are greater on PET/CT than
PET/MR. This difference is however corrected for in
the calculation of TBRMAX values.
• The Dixon method of PET/MR attenuation correction
is consistently affected by extra-cardiac artifacts. This
problem is largely resolved with the use of a free-
breathing radial GRE attenuation correction
sequence.
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